Latest News & Features
article
The law of innovation balances private returns on investment against benefits to the public. Increasing the profitability of intellectual property acts as an inducement to spend money on research and testing, but threatens to increase costs to the public both directly and in terms of reduced access. 21 April 2021
Americas
Law firm Withers has expanded its US tech practice with the hire of a new team of life sciences and venture capital-focused lawyers in Boston. 20 April 2021
Plant Varieties
Just under a decade ago, Washington became the first state to legalise recreational cannabis, bringing with it the potential to create a legitimate business focused on the buying, selling or distribution of the drug in the US. 20 April 2021
Big Pharma
Pfizer has settled lawsuits against two Indian generics makers who had informed the US Food and Drug Administration of plans to launch their own version of Xeljanz XR. 20 April 2021
Americas
A group of more than 170 former world leaders and Nobel Laureates has called upon US President Joe Biden to waive IP rights for COVID vaccines, in an open letter posted yesterday. 15 April 2021
Generics
The Fifth Circuit of the Court of Appeals has denied a petition from Impax Laboratories to overturn a decision finding Impax engaged in an illegal pay-for-delay settlement with Endo Pharmaceuticals. 15 April 2021
article
The number of patent applications containing the word Cannabis has skyrocketed over the past few years, particularly in the US. As the laws and stance towards medicinal use and recreational use of cannabis change, this market is only expected to grow. As competition increases and the market expands the value of cannabis-related IP and the risks of failing to protect it expand also. Join us as we discuss: 15 April 2021
Big Pharma
Amgen subsidiary Immunex has asked the US Supreme Court not to review a Federal Circuit decision that found the company did not patent the same rheumatoid arthritis invention twice. 14 April 2021
Generics
Repurposing drugs has very clear benefits. It gives companies the opportunity to develop entirely new uses for existing drugs that they don’t have patent protection, and may allow innovator companies to protect a molecule or formulation even after initial patent protection has expired. 13 April 2021
Big Pharma
Edwards Lifesciences will be able to proceed with its claims of trademark infringement over an artificial heart valve against Meril Life Sciences, according to a US federal court. 13 April 2021